Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds
The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of alpha, beta unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound.
1 .- 50 . (canceled)
51 . A composition comprising oxymorphone and containing about 0.001% or less, by weight of said oxymorphone, of an α,β unsaturated ketone.
52 . The composition of claim 51 wherein said α,β unsaturated ketone is 14-hydroxymorphinone or 14-hydroxycodienone.
53 . The composition of claim 51 wherein said α,β unsaturated ketone is 14-hydroxymorphinone.
54 . The composition of claim 51 wherein said α,β unsaturated ketone is 14-hydroxymorphinone or 14-hydroxycodienone and no 14-hydroxymorphinone or 14-hydroxycodienone is detectable by high performance liquid chromatography with mass spectrometry detection.
55 . The composition of claim 51 wherein said α,β unsaturated ketone is 14-hydroxymorphinone and said composition comprises about 0.0005% or less, by weight of said oxymorphone, of 14-hydroxymorphinone.
56 . The composition of claim 51 wherein said α,β unsaturated ketone is 14-hydroxymorphinone or 14-hydroxycodienone and said composition comprises about 0.0005% or less, by weight of said oxymorphone, of 14-hydroxymorphinone or 14-hydroxycodienone.
57 . The composition of claim 51 , wherein the oxymorphone is an oxymorphone salt.
58 . The composition of claim 53 , wherein the oxymorphone is an oxymorphone salt.
59 . The composition of claim 55 , wherein the oxymorphone is an oxymorphone salt.
60 . The composition of claim 51 , wherein the oxymorphone is oxymorphone HCl.
61 . The composition of claim 53 , wherein the oxymorphone is oxymorphone HCl.
62 . The composition of claim 55 , wherein the oxymorphone is oxymorphone HCl.
63 . A pharmaceutical formulation comprising oxymorphone and containing about 0.001% or less, by weight of said oxymorphone, of an α,β unsaturated ketone.
64 . The pharmaceutical composition of claim 63 wherein said α,β unsaturated ketone is 14-hydroxymorphinone or 14-hydroxycodienone.
65 . The pharmaceutical composition of claim 63 wherein said α,β unsaturated ketone is 14-hydroxymorphinone.
66 . The pharmaceutical composition of claim 63 comprising about 0.0005% or less, by weight of said oxymorphone, of an α,β unsaturated ketone.
67 . The pharmaceutical composition of claim 63 comprising about 0.0005% or less, by weight of said oxymorphone, of 14-hydroxymorphinone.
68 . The pharmaceutical composition of claim 63 wherein said oxymorphone is oxymorphone HCl.
69 . The pharmaceutical composition of claim 65 wherein said oxymorphone is oxymorphone HCl.
70 . The pharmaceutical composition of claim 67 wherein said oxymorphone is oxymorphone HCl.